Abstract
Hyperprolactinemia is a common adverse reaction in patients with schizophrenia who take antipsychotic drugs; it often leads to treatment non-compliance in patients and has an adverse effect on their prognosis. This study aimed to explore the risk factors of elevated prolactin (PRL) caused by risperidone (RIS) and olanzapine (OLZ) and the relationship between PRL and fasting plasma glucose and lipids. Patients with schizophrenia were divided into two groups: 264 patients who were taking RIS and 175 patients who were taking OLZ. These two groups were further divided according to serum PRL levels: an elevated PRL group (>30 ng/mL) and a normal PRL group (PRL ≤30 ng/mL). The demographics, medication dosage, fasting plasma glucose, total cholesterol and triglycerides were compared in the two groups. Logistic regression analysis was performed to explore the risk factors of elevated PRL levels. Compared with the OLZ group, the RIS group had a greater number of patients with elevated PRL (155/264 vs 58/175). Either the RIS or the OLZ group, the proportion of elevated PRL was greater in female patients (RIS: χ2=6.76, p=0.009; OLZ: χ2=12.98, p<0.001) and with higher doses of the related drugs (RIS: U=-3.73, p<0.001; OLZ: U=-2.31, p=0.021...Continue Reading
References
Jan 13, 2001·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·A E KearnsG H Daniels
Mar 26, 2003·Psychoneuroendocrinology·Bruce J KinonUriel M Halbreich
Apr 8, 2003·The Journal of Clinical Endocrinology and Metabolism·Charlotte LingHåkan Billig
Dec 10, 2003·Archives of General Psychiatry·Patrick F SullivanMichael C Neale
May 11, 2005·Biochemical and Biophysical Research Communications·Louise NilssonHåkan Billig
Jun 26, 2007·Diabetes, Obesity & Metabolism·T BrandebourgN Ben-Jonathan
Jul 4, 2007·Journal of Psychopharmacology·Chris Bushe, Michael Shaw
Mar 13, 2008·The Journal of Clinical Endocrinology and Metabolism·Jennifer S LeeSteven R Cummings
Aug 16, 2008·Journal of Psychopharmacology·Peter Fitzgerald, Timothy G Dinan
Nov 28, 2008·Endocrinology·Carol HuangJames C Cross
Feb 3, 2009·The British Journal of Psychiatry : the Journal of Mental Science·Magali HaasVivek Kusumakar
Feb 19, 2009·Clinical Endocrinology·Anne CaufriezGeorges Copinschi
Mar 25, 2009·Endocrinology·Robert L Sorenson, Todd C Brelje
May 11, 2011·Diabetes/metabolism Research and Reviews·Sunmin ParkSung-Hoon Kim
Jan 24, 2013·Diabetes Care·Tiange WangGuang Ning
Aug 10, 2013·L'Encéphale·I BesnardC Roberge
Jan 1, 2014·Progress in Molecular Biology and Translational Science·Yao Huang, Yongchang Chang
Jul 2, 2015·JAMA Psychiatry·Ariel Graff-GuerreroDavid C Mamo
Nov 20, 2016·The Lancet. Psychiatry·Anita Riecher-Rössler
Feb 23, 2017·Schizophrenia Research·Benedicto Crespo-FacorroRosa Ayesa-Arriola
Jan 23, 2018·Journal of Child and Adolescent Psychopharmacology·Lei XiaXiang-Yang Zhang
Jun 27, 2019·Diabetes & Metabolic Syndrome·Hatice OzisikSevki Cetinkalp
Jul 16, 2019·Lancet·Maximilian HuhnStefan Leucht